GMAB vs JAZZ
Genmab A/S and Jazz Pharmaceuticals plc, both Healthcare
Genmab A/S is the larger company at $16B against $14B. Over the past year JAZZ returned +70% against +31% for GMAB. The RyuScore puts GMAB ahead, 84 against 48 out of 100.
| Figure | GMAB | JAZZ |
|---|---|---|
| Last close | $37.06 | $218 |
| Market cap | $16B | $14B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 14.9 |
| 1-year return | +31% | +70% |
| 5-year return | -15% | +62% |
| RyuScoresector-relative, 1–10 | 84/100 | 48/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Jazz Pharmaceuticals plc
Revenue of $1.2B in Q2 2026, net income $193M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.